Literature DB >> 21756281

A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.

Tahlita C M Zuiverloon1, Willemien Beukers, Kirstin A van der Keur, Jesrael R Munoz, Chris H Bangma, Hester F Lingsma, Marinus J C Eijkemans, Jan P Schouten, Ellen C Zwarthoff.   

Abstract

OBJECTIVE: To develop a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay for the detection of non-muscle invasive bladder cancer (NMIBC) recurrences in voided urine. PATIENTS AND METHODS: Genes frequently methylated in NMIBC tumours (n= 37) were selected to develop a BC-specific MS-MLPA assay. Genes methylated in blood from patients with BC (n= 29) and genes methylated in urine from patients with no history of BC (n= 46) were excluded. A four-gene panel with the highest predictive value was selected from the initial assay. This four-gene panel was tested and validated on urine from patients with a histologically confirmed recurrence (n= 68 test set; n= 49 validation set) and urine samples from patients without BC (n= 91, test set) and urine from recurrence-free BC (rec-free BC) patients (n= 60, validation set). A model was developed to predict the probability of having a recurrence based on methylation of the four-gene panel and a threshold probability with the highest sensitivity and specificity was determined. The outcome of the model was validated on BC urine samples (n= 65) and on urine samples from rec-free BC patients (n= 29).
RESULTS: The BC MS-MLPA assay consisted of 23 methylation probes. The selected four-gene panel included: APC_a, TERT_a, TERT_b, and EDNRB. This panel reached an area under the receiver operating characteristic curve (AUC) of 0.82 (test set) and AUC 0.69 (validation set). Sensitivity and specificity for the detection of a concomitant tumour were 63.3% and 58.3% respectively (test set) and 72.3% and 55.2%, respectively (validation set).
CONCLUSIONS: We have developed a methylation detection assay specifically for the detection of recurrences in patients with NMIBC in voided urine. The findings are promising and improvement of this test could eventually contribute to a more individualized patient friendly surveillance.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756281     DOI: 10.1111/j.1464-410X.2011.10428.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  26 in total

1.  Hypermethylation in bladder cancer: biological pathways and translational applications.

Authors:  Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2012-01-25

Review 2.  What is new in non-muscle-invasive bladder cancer in 2016?

Authors:  Ashish M Kamat; Murat Bağcıoğlu; Emre Huri
Journal:  Turk J Urol       Date:  2017-03-01

Review 3.  DNA methylation-based biomarkers in bladder cancer.

Authors:  Raju Kandimalla; Angela A van Tilborg; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2013-04-30       Impact factor: 14.432

Review 4.  Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.

Authors:  V Urquidi; C J Rosser; S Goodison
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 5.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 6.  High-altitude adaptation in humans: from genomics to integrative physiology.

Authors:  Priti Azad; Tsering Stobdan; Dan Zhou; Iain Hartley; Ali Akbari; Vineet Bafna; Gabriel G Haddad
Journal:  J Mol Med (Berl)       Date:  2017-09-26       Impact factor: 4.599

7.  Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors.

Authors:  Rodrigo García-Baquero; Patricia Puerta; Manuel Beltran; Miguel Alvarez-Mújica; Jose Luis Alvarez-Ossorio; Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2014-02-28

Review 8.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

9.  Endothelin receptor B, a candidate gene from human studies at high altitude, improves cardiac tolerance to hypoxia in genetically engineered heterozygote mice.

Authors:  Tsering Stobdan; Dan Zhou; Eilleen Ao-Ieong; Daniel Ortiz; Roy Ronen; Iain Hartley; Zhuohui Gan; Andrew D McCulloch; Vineet Bafna; Pedro Cabrales; Gabriel G Haddad
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-03       Impact factor: 11.205

10.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.